Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279313 · ClinicalTrials.gov registry record · Phase 3
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
A Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Active
- Registry status
- Phase 3
- Development phase
- 680
- Enrollment target
- 20
- Study locations
NCT05279313: Active Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT05279313 is a Phase 3 study of Attention Deficit Hyperactivity Disorder that is active but no longer recruiting, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 680 participants, above the 210-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (224% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05279313, a Phase 3 study of Attention Deficit Hyperactivity Disorder, is active but no longer recruiting, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 680 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate long-term safety exposure
Conditions Studied
Interventions
- DRUG Centanafadine Hydrochloride
Study Locations (20)
California
- Care Access - Beverly Hills
- Proscience Research Group - Culver City
- Sun Valley Research Center, Inc. - Imperial
- Long Beach Clinical Trials Services, Inc - Long Beach
- NRC Research Institute - Orange
- SDS Clinical Trials Inc - Santa Ana
- CMB Clinical Trials - Santee
- Pacific Clinical Research Management Group LLC - Upland
Florida
- Sarkis Clinical Trials - Gainesville
- Direct Helpers Research Center - Hialeah
- Reliable Clinical Research, LLC - Hialeah
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- West Broward Outpatient Site - Lauderhill
Alabama
- Harmonex Neuroscience Research - Dothan
- The Center for Clinical Trials, Inc. - Saraland
Arkansas
- Preferred Research Partners, Inc. - Little Rock
- Woodland International Research Group - Little Rock
Arizona
- Southwest Autism Research and Resource Center - Phoenix
Colorado
- MCB Clinical Research Centers - Colorado Springs
Connecticut
- Mindscapes Counseling LLC DBA Comprehensive Psychiatric Care, PC - Norwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 3 |
What the registry record for NCT05279313 still lists
NCT05279313 is an interventional study that assigns participants to a tested intervention. The registered 680 participants enrollment target is mid-sized for trials with a published cap, above the 210-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (224% higher).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Centanafadine Hydrochloride is the first listed.
NCT05279313 names 20 study sites across 7 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05279313 about?
NCT05279313 is a clinical study titled "A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.". To evaluate long-term safety exposure
What is the current status of trial NCT05279313?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 680 participants. The study started on 2022-02-24. Estimated completion is 2026-04-30.
What conditions does trial NCT05279313 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT05279313?
The interventions under investigation include: Centanafadine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05279313?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279313 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05279313's enrollment target sits among peer trials
680 7th of 102 higher than 96 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
COMPLETED · Phase 3
-
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
COMPLETED · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI